Shou-Ching Jaminet

Company: Angiex

Job title: Founder

Seminars:

Panel Discussion: What Is the Next Generation of ADC Targets? 11:00 am

Discussing current developments in validate ADC targets, ADC and IO combination therapy for tumor eradication rather than temporary tumor regression Exploring novel targets with non-conventional (non-clathrin-mediated) internalization pathways; targets with expression in the tumor microenvironment e.g. angiogenic blood vessels Discovering the future of ADC targets that can internalize to intracellular space and by passing the…Read more

day: Conference Day One